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transcripts currently detected come only from proliferating
leukemia cells and while leukemia stem cells may not tran-
scribe the BCR-ABL gene. Will digital PCR increase the
sensitivity of a RT-PCR? Should we be studying CML patients
posttransplantation with techniques designed to mobilize
leukemia stem cells from their niche?
Much has been achieved in the treatment of CML trans-
plantations and TKIs in recent years. Many fascinating
questions remain to be addressed.
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Accepted 20 February 2013Since the ﬁrst reports of its efﬁcacy for myeloma in the
early 1960s [1-3], melphalan has remained a key component
of the oncologist’s armamentarium. High-dose melphalan
therapy was introduced in the early 1980s [4] and has since
been employed with stem cell rescue for “younger”
myeloma patients, with the age limit now pushing 75 years
with advances in supportive care measures [5]. The era of
novel drug development has reawakened the debate of
whether or not to approach the disease with a curative
intent [6]. Some investigators have gone as far as proposing
a pre-emptive strike with novel agent combinations in
smoldering myeloma [7], but a similar approach with
thalidomide has not provided improvements in overall
survival [8]. The Arkansas Myeloma investigators have been
proponents of a curative approach long before the era of
novel agents, proposing the Total Therapy (TT) program that
applies all effective antimyeloma therapies up front to
eradicate all disease subclones and reduce the chance for
drug resistance [9]. Melphalan has been at the front andcenter of the TT program, employed in high doses twice with
stem cell rescue. To this day, myeloma therapy for
transplant-eligible patients follows the TT paradigm in many
ways; the only major difference has been the replacement of
cytotoxic drugs with novel agents as induction, consolida-
tion, and maintenance. Regardless of the therapeutic
approach, most myeloma patients today relapse sooner or
later after having received ﬁrst-line therapy. High-dose
melphalan with stem cell rescue remains a viable option
for salvage therapy, even with the growing number of novel
drugs for relapsed and/or refractory myeloma.
In the current issue, Michaelis et al. [10] report on the role
of employing high-dose melphalan with stem cell rescue as
salvage therapy for relapsed and/or refractory myeloma.
Using the Center for International Blood and Marrow
Transplantation database, a retrospective study was con-
ducted on 187 patients between 1995 and 2008 who had
previously received an autologous hematopoietic stem cell
transplant (AHCT-1) as part of initial myeloma therapy and
subsequently received a second AHCT (AHCT-2) at the time
of disease relapse or progression. The nonrelapse mortality
was reported at 2% at the 1-year mark and 4% at the 2-year
and 3-year intervals, suggesting that AHCT-2 is a safe
option. It is also clear that AHCT-2 is likely noncurative for
the majority of patients in this analysis, as only 5% of patients
enjoy long-term disease control with longer follow-ups
(progression-free survival 47% at 1 year; 13% at 3 years; 5%
at 5 years). The multivariate analyses reveal that patients
who relapse after 36 months from AHCT-1 are those who
beneﬁt the most from AHCT-2. A further subgroup analysis
by time stratiﬁcation shows that patients receiving AHCT-2
after the year 2004 have superior outcome compared to
S.Z. Usmani / Biol Blood Marrow Transplant 19 (2013) 679e681 681the earlier time cohort, which likely reﬂects the use and
availability of novel agents at further relapses. Taken
together, the data suggest that AHCT-2 is a safe option for
patients with late relapses after AHCT-1. The authors propose
prospective clinical investigations to evaluate the sequence
of AHCT-2 in the relapsed/refractory myeloma patients,
especially with the plethora of novel antimyeloma agents in
the drug development pipeline.
There are several smaller published studies [11-15] that
support Michaelis et al., including a study supporting salvage
AHCTeven after tandem autologous stem cell transplant [16].
Given the fact that melphalan continues to prove its worth in
the salvage setting, it may make sense to collect more
autologous stem cells as an “insurance policy” (goal 10 to
15 million CD34 cells per kilogram of body weight) at the
time of AHCT-1 than what is the general practice today. Such
an approach, in turn, may also be useful for long-term
survivors who go on to develop secondary hematopoietic
malignancies.
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